Mesoblast Limited is ranked as one of the 10 Best Mid Cap Stocks to Buy According to Billionaires. The company launched the first cell therapy, Ryoncil, for children with acute graft versus host disease. Ryoncil now benefits from seven years of orphan drug exclusivity and biologic exclusivity until 2036, with intellectual property protection through 2044.

Mesoblast Limited is a global leader in cellular medicines, focusing on severe inflammatory diseases with limited treatment options. The company’s lead product, Ryoncil, is the first FDA-approved mesenchymal stromal cell therapy for children with steroid-refractory acute GVHD. The drug has been rapidly launched, partnering with major U.S. transplant centers and securing insurance coverage for over 250 million lives.

The corporation’s manufacturing processes allow scalable production of consistent cell therapies without the need for donor-recipient matching. Mesoblast Limited is also advancing other candidates, including Revascor for ischemic heart failure and a Phase 3 program for chronic discogenic low back pain. The company offers a non-opioid alternative for patients seeking treatment.

While Mesoblast Limited presents potential as an investment, some believe AI stocks offer greater upside potential with less downside risk. For those seeking an undervalued AI stock poised to benefit from current trends, consider exploring the best short-term AI stock.

Read more at Yahoo Finance: Mesoblast Limited (MESO) Launches First Cell Therapy for Children